Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 21.37% is in line with its 5-year average of 23.09%, around the middle of its 5-year range (15.01%–27.02%).
1.83% below its 12-month average of 21.77%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 22.41%.
GROSS MARGIN
21.37%
GROSS MARGIN AVG TTM
21.77%
GROSS MARGIN AVG 3Y
23.35%
GROSS MARGIN AVG 5Y
23.09%
GROSS MARGIN AVG 10Y
23.50%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.83%
CURRENT VS 3Y AVG
-8.50%
CURRENT VS 5Y AVG
-7.46%
CURRENT VS 10Y AVG
-9.06%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-48.14%
vs the sector median at left
Surgery Partners, Inc.
Market Cap
$1.75B
Gross Margin
21.37%
TTM Avg
21.77%
3Y Avg
23.35%
5Y Avg
23.09%
Market Cap
$1.74B
Gross Margin
-319.36%
TTM Avg
-798.46%
3Y Avg
-813.46%
5Y Avg
-704.28%
Market Cap
$1.77B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$1.74B
Gross Margin
83.34%
TTM Avg
81.78%
3Y Avg
81.39%
5Y Avg
75.51%
Market Cap
$1.74B
Gross Margin
12.55%
TTM Avg
11.67%
3Y Avg
11.80%
5Y Avg
12.59%
Market Cap
$1.73B
Gross Margin
76.47%
TTM Avg
79.35%
3Y Avg
79.86%
5Y Avg
39.87%
Market Cap
$1.71B
Gross Margin
49.52%
TTM Avg
50.81%
3Y Avg
52.12%
5Y Avg
52.25%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Surgery Partners, Inc. (SGRY) | $1.75B | 21.37% | 21.77% | 23.35% | 23.09% |
| Novocure Ltd (NVCR)vs › | $1.74B | 76.13% | 75.94% | 76.33% | 77.05% |
| Absci Corporation (ABSI)vs › | $1.74B | -319.36% | -798.46% | -813.46% | -704.28% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | 100.00% | 100.00% | 100.00% | 100.00% |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | 83.34% | 81.78% | 81.39% | 75.51% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 12.55% | 11.67% | 11.80% | 12.59% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | 76.47% | 79.35% | 79.86% | 39.87% |
| Personalis, Inc. (PSNL)vs › | $1.71B | 22.65% | 27.17% | 24.91% | 27.04% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 49.52% | 50.81% | 52.12% | 52.25% |
| Xencor, Inc. (XNCR)vs › | $1.81B | 91.63% | -7.22% | 16.08% | 9.32% |
Gross Margin
21.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 22.41% |
| 2026-03-31 | 15.01% |
| 2025-12-31 | 23.98% |
| 2025-09-30 | 23.77% |
| 2025-06-30 | 23.67% |
| 2025-03-31 | 20.86% |
| 2024-12-31 | 27.02% |
| 2024-09-30 | 23.04% |
| 2024-06-30 | 23.51% |
| 2024-03-31 | 21.65% |
| 2023-12-31 | 26.33% |
| 2023-09-30 | 24.60% |
| 2023-06-30 | 23.08% |
| 2023-03-31 | 20.11% |
| 2022-12-31 | 26.06% |
| 2022-09-30 | 21.14% |
| 2022-06-30 | 21.87% |
| 2022-03-31 | 20.93% |
| 2021-12-31 | 24.11% |
| 2021-09-30 | 21.91% |
| 2021-06-30 | 21.77% |
| 2021-03-31 | 20.20% |
| 2020-12-31 | 24.69% |
| 2020-09-30 | 23.02% |
| 2020-06-30 | 14.79% |
| 2020-03-31 | 16.96% |
| 2019-12-31 | 24.98% |
| 2019-09-30 | 21.88% |
| 2019-06-30 | 23.57% |
| 2019-03-31 | 21.76% |
| 2018-12-31 | 26.76% |
| 2018-09-30 | 24.70% |
| 2018-06-30 | 23.54% |
| 2018-03-31 | 21.58% |
| 2017-12-31 | 26.42% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 24.94% |
| 2017-03-31 | 25.94% |
| 2016-12-31 | 29.98% |
| 2016-09-30 | 28.76% |
| 2016-06-30 | 27.90% |
| 2016-03-31 | 26.35% |
| 2015-12-31 | 30.44% |
| 2015-09-30 | 29.54% |
| 2015-06-30 | 30.61% |
| 2015-03-31 | 30.50% |
| 2014-12-31 | 32.89% |
| 2014-09-30 | 40.53% |
| 2014-06-30 | 39.87% |
| 2014-03-31 | 37.75% |
